- Home
- ZYME vs HEPS Comparison
ZYME vs HEPS Comparison
Compare ZYME & HEPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYME
- HEPS
- Stock Information
- Founded
- ZYME 2003
- HEPS 2000
- Country
- ZYME United States
- HEPS Turkey
- Employees
- ZYME N/A
- HEPS N/A
- Industry
- ZYME Biotechnology: Pharmaceutical Preparations
- HEPS Catalog/Specialty Distribution
- Sector
- ZYME Health Care
- HEPS Consumer Discretionary
- Exchange
- ZYME Nasdaq
- HEPS Nasdaq
- Market Cap
- ZYME 983.6M
- HEPS 1.1B
- IPO Year
- ZYME 2017
- HEPS 2021
- Fundamental
- Price
- ZYME $11.91
- HEPS $2.85
- Analyst Decision
- ZYME Buy
- HEPS
- Analyst Count
- ZYME 6
- HEPS 0
- Target Price
- ZYME $19.50
- HEPS N/A
- AVG Volume (30 Days)
- ZYME 728.6K
- HEPS 723.9K
- Earning Date
- ZYME 03-05-2025
- HEPS 04-08-2025
- Dividend Yield
- ZYME N/A
- HEPS N/A
- EPS Growth
- ZYME N/A
- HEPS N/A
- EPS
- ZYME N/A
- HEPS N/A
- Revenue
- ZYME $76,304,000.00
- HEPS $1,167,077,294.00
- Revenue This Year
- ZYME $19.85
- HEPS $43.21
- Revenue Next Year
- ZYME $100.06
- HEPS $37.58
- P/E Ratio
- ZYME N/A
- HEPS N/A
- Revenue Growth
- ZYME 0.38
- HEPS 82.39
- 52 Week Low
- ZYME $7.97
- HEPS $1.25
- 52 Week High
- ZYME $17.70
- HEPS $4.05
- Technical
- Relative Strength Index (RSI)
- ZYME 40.19
- HEPS 36.74
- Support Level
- ZYME $12.15
- HEPS $2.90
- Resistance Level
- ZYME $13.28
- HEPS $3.09
- Average True Range (ATR)
- ZYME 0.60
- HEPS 0.15
- MACD
- ZYME 0.03
- HEPS -0.02
- Stochastic Oscillator
- ZYME 22.22
- HEPS 33.33
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About HEPS D-Market Electronic Services & Trading
D-MARKET Electronic Services & Trading offers an e-commerce platform in Turkey and the surrounding region. The company is comprised of one reportable segment, namely e-commerce operations. The Group derives revenue from the sales of goods, marketplace revenues, and other revenues.